Cargando…

Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function

Daprodustat is a hypoxia‐inducible factor‐prolyl hydroxylase inhibitor in development for treatment of anemia of chronic kidney disease. We evaluated the role of hepatic impairment on daprodustat pharmacokinetics, pharmacodynamics, and tolerability. Participants with mild (Child‐Pugh Class A, score...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahar, Kelly M., Shaddinger, Bonnie C., Ramanjineyulu, Bandi, Andrews, Susan, Caltabiano, Stephen, Lindsay, Alistair C., Cobitz, Alexander R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310628/ https://www.ncbi.nlm.nih.gov/pubmed/35355447 http://dx.doi.org/10.1002/cpdd.1090

Ejemplares similares

Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure
por: Caltabiano, Stephen, et al.
Publicado: (2019)

Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination
por: Mahar, Kelly M., et al.
Publicado: (2021)

The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects
por: Caltabiano, Stephen, et al.
Publicado: (2018)

A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis
por: Bailey, Christine K., et al.
Publicado: (2019)

An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects
por: Cizman, Borut, et al.
Publicado: (2018)

A Single‐Dose, Open‐Label, Randomized, Two‐Way Crossover Study in Healthy Japanese Participants to Evaluate the Bioequivalence and the Food Effect on the Pharmacokinetics of Daprodustat
por: Yamada, Masanori, et al.
Publicado: (2020)

Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients
por: Kanai, Hidetoshi, et al.
Publicado: (2021)

Daprodustat: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan
por: Nangaku, Masaomi, et al.
Publicado: (2022)

Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis
por: Meadowcroft, Amy M, et al.
Publicado: (2018)

Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
por: Macdougall, Iain C., et al.
Publicado: (2023)

Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease
por: Holdstock, Louis, et al.
Publicado: (2018)

Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial
por: Singh, Ajay K., et al.
Publicado: (2022)

Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
por: Ishii, Taisuke, et al.
Publicado: (2021)

Daprodustat: A potential game-changer in renal anemia therapy—A perspective
por: Haider, Muhammad Usman, et al.
Publicado: (2023)

Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment
por: Hossain, Mohammad, et al.
Publicado: (2021)

Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
por: Wang, Ellen Q., et al.
Publicado: (2021)

An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat
por: Becker, Kimberly A., et al.
Publicado: (2017)

Daprodustat Accelerates High Phosphate-Induced Calcification Through the Activation of HIF-1 Signaling
por: Tóth, Andrea, et al.
Publicado: (2022)

Daprodustat for anaemia in patients with heart failure and chronic kidney disease: A randomized controlled study
por: Iso, Takashi, et al.
Publicado: (2022)

Pharmacokinetics of Glutathione and Its Metabolites in Normal Subjects
por: Hong, Sae-Yong, et al.
Publicado: (2005)

Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis
por: Zheng, Qiyan, et al.
Publicado: (2021)

Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
por: Wang, Ellen Q., et al.
Publicado: (2022)

Investigation of the human metabolism and disposition of the prolyl hydrolase inhibitor daprodustat using IV microtracer with Entero‐Test bile string
por: Tai, Guoying, et al.
Publicado: (2023)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
por: Frey, Reiner, et al.
Publicado: (2013)

Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12
por: Liu, Yong, et al.
Publicado: (2016)

Efficacy and Safety of Daprodustat Vs rhEPO for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis
por: Fu, Zhangning, et al.
Publicado: (2022)

Efficacy of Different Doses of Daprodustat for Anemic Non-dialysis Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis
por: Fadlalmola, Hammad, et al.
Publicado: (2022)

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics
por: Marbury, Thomas C., et al.
Publicado: (2017)

The pharmacokinetics of anthocyanins and their metabolites in humans
por: de Ferrars, R M, et al.
Publicado: (2014)

Brigatinib pharmacokinetics in patients with chronic hepatic impairment
por: Hanley, Michael J., et al.
Publicado: (2023)

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
por: Tan, Antoinette R., et al.
Publicado: (2015)

Issues in the Pharmacokinetics of Trichloroethylene and Its Metabolites
por: Chiu, Weihsueh A., et al.
Publicado: (2006)

A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
por: Ermer, James, et al.
Publicado: (2016)

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
por: Marzin, Kristell, et al.
Publicado: (2017)

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
por: Morcos, Peter N., et al.
Publicado: (2018)

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib
por: Piscitelli, Joseph, et al.
Publicado: (2022)

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine
por: Nafziger, Anne N., et al.
Publicado: (2019)

Pharmacokinetics of Tyrosol Metabolites in Rats
por: Lee, Da-Hye, et al.
Publicado: (2016)

Understanding the pharmacokinetics of prodrug and metabolite
por: Cho, Seungil, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vimivpaqb72ts85mosjuej252o